Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

Core Viewpoint - Alzamend Neuro, Inc. is set to present its innovative research on AL001, a novel lithium-delivery system, at the Military Health System Research Symposium, highlighting its potential benefits for treating PTSD and other mental health disorders in military personnel and veterans [1][2]. Company Overview - Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder [9]. - The company’s pipeline includes two main drug candidates: AL001, a patented ionic cocrystal technology for lithium delivery, and ALZN002, a cell-based therapeutic vaccine aimed at combating Alzheimer's [9]. Research Presentation Details - The poster presentation titled "Quantitate Differences in Lithium Brain-to-Plasma Exposure in PTSD Subjects Between AL001 and Lithium Carbonate" will take place on August 6, 2025, at the Gaylord Palms Resort & Convention Center [4][5]. - The session will focus on innovations in military suicide prevention and related research [5]. Study Objectives - The study aims to quantify differences in lithium exposure in the brain versus plasma in PTSD subjects, comparing AL001 with traditional lithium carbonate [6]. - This research is part of a broader effort to create a composite database that includes data from various neurodegenerative and neuropsychiatric disorders [6]. AL001 Characteristics - AL001 is designed to provide the benefits of lithium while minimizing toxicities associated with conventional lithium salts, potentially improving safety and efficacy [7]. - Results from a completed Phase IIA study indicated a maximum tolerated dose that does not require therapeutic drug monitoring, suggesting a favorable safety profile [7]. Clinical Trials - Alzamend initiated the first of five Phase II clinical studies of AL001 in May 2025, focusing on healthy human subjects to establish baseline data for future studies in patients with Alzheimer's, BD, MDD, and PTSD [8]. - Previous animal studies indicated that AL001 allows for better brain absorption of lithium while maintaining lower blood levels, which could lead to safer treatments [8].